Guoqiang Wang

This inventor holds 112 USPTO granted patents and 20 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in Antiviral Agents (CPC class C07J9-005). Top assignees: Enanta Pharmaceuticals, Inc., Abbvie Inc., Elmore Patent Law Group, P.c.. Active years: 2003-2026.

USPTO Granted Patents = 112 (Patent Applications = 20)

% Patents Active = 80.4

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 10 (Patent Applications = 25)

Average Co-Inventor Count = 5.7

ph-index = 12

Forward Citations = 601(Granted Patents)

Forward Citations (Not Self Cited) = 329(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Cambridge, MA (US) (2004)
Belmont, MA (US) (2003 - 2024)

Company Filing History:

109 out of 298

Enanta Pharmaceuticals, Inc.

Elmore Patent Law Group, P.c.

patent

4. 1 out of 1

Enata Pharmacueticals, Inc.

patent

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Apoptosis Signal-Regulating Kinase 1

Spiropyrrolidine

Antiviral Agents

Bile Acid Derivatives

Tetrazole

Heterocyclic Compounds

FXR Agonists

17-Beta-Hydroxysteroid Dehydrogenase

Cycloalkyl Compounds

Sulfonyl Carbamate

Isoxazole Derivatives

Macrocyclic Compounds

112 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747248 - Processes for the preparation of substituted spirooxindole derivatives (2026-09-29),

2. 12643905 - Spiropyrrolidine derived antiviral agents (2026-06-02),

3. 12552777 - Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof (2026-02-17),

4. 12540141 - Spiropyrrolidine derived antiviral agents (2026-02-03),

5. 12479854 - Spiropyrrolidine derived antiviral agents (2025-11-25),

6. 12459923 - Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof (2025-11-04),

7. 12398147 - Macrocyclic spiropyrrolidine derived antiviral agents (2025-08-26),

8. 12384753 - 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof (2025-08-12),

9. 12281140 - Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof (2025-04-21),

10. 12018017 - Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof (2024-06-25),

11. 12006291 - Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid (2024-06-11),

12. 11976084 - Spiropyrrolidine derived antiviral agents (2024-05-07),

13. 11958879 - Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof (2024-04-16),

14. 11945824 - Heterocyclic compounds as anti-viral agents (2024-04-02),

15. 11919910 - Spiropyrrolidine derived antiviral agents (2024-03-05),

Title: The Innovations of Inventor Guoqiang Wang

Introduction:

Guoqiang Wang, a prolific inventor based in Belmont, MA (US), has made significant contributions to the field of pharmaceuticals with over 100 patents to his name. His groundbreaking work in developing compounds and pharmaceutical compositions has propelled advancements in treating various diseases and conditions.

Latest Patents:

1. Bile acid derivatives as FXR/TGR5 agonists: Wang's invention focuses on compounds represented by Formula I, designed as treatments for FXR-mediated or TGR5-mediated diseases. The pharmaceutical compositions derived from these compounds offer promising methods for addressing related health issues.

2. Heterocyclic compounds as anti-viral agents: Wang's patent reveals compounds effective in inhibiting Respiratory Syncytial Virus (RSV) or HMPV. The pharmaceutical compositions utilizing these compounds show potential in treating subjects suffering from RSV or HMPV infections.

Career Highlights:

Guoqiang Wang has held prominent positions at Enanta Pharmaceuticals, Inc. and AbbVie Inc., where he showcased his innovative prowess in developing novel pharmaceutical solutions. His leadership and expertise have been instrumental in advancing the pharmaceutical industry.

Collaborations:

Throughout his career, Wang has collaborated closely with esteemed colleagues like Yat Sun Or and Jiang Long. Together, they have worked on cutting-edge projects that have pushed the boundaries of pharmaceutical research and development.

Conclusion:

Inventor Guoqiang Wang's relentless pursuit of innovation and his numerous patents in the pharmaceutical domain underscore his commitment to improving healthcare outcomes. His visionary contributions have not only revolutionized the field of pharmaceuticals but also paved the way for future advancements in medical treatments.